Advertisement
Advertisement
MOST RECENT
Advertisement
Popular
Featured Trials
An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)
An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)
Sign up for our emails
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Newsletter
Privacy Policy
Tislelizumab + Chemo vs. Placebo + Chemo as 1L Treatment for Advanced Esophageal Cancer
KEY TAKEAWAYS A phase 3, RATIONALE-306 study that was global, randomized, double-blind, parallel-arm, and placebo-controlled was carried out at 162 medical centers in Asia, Europe, Oceania, and North America. The present study provides interim analysis outcomes...
Survival Analysis of Ribociclib + Endocrine Therapy in HR+/HER2- ABC Patients With Visceral Metastases
KEY TAKEAWAYS A Phase 3 MONALEESA-3 trial investigated the efficacy of RIB and ET in patients with hormone receptor-positive, and HER2-negative advanced breast cancer. The study’s primary aim was to evaluate the impact of RIB in combination with ET on PFS and OS in...
A Study of Sacituzumab Govitecan in Metastatic Breast Cancer
KEY TAKEAWAYS A Phase III TROPiCS-02 trial compared efficacy of SG to physician's choice chemotherapy in endocrine-resistant, HR+/HER2- breast cancer. The primary aim was to evaluate the PFS through a blinded independent central review. SG showed a 34% decrease in...
ARIEL4: Rucaparib vs Standard Chemotherapy for Relapsed Ovarian Cancer With BRCA1/2 Mutation
KEY TAKEAWAYS A phase 3 trial (ARIEL4) evaluated the efficacy of rucaparib compared to chemotherapy in managing ovarian carcinoma in patients with BRCA1 or BRCA2 mutations. The primary aim was to assess investigator-assessed progression-free survival in the...
Atezolizumab and Chemotherapy for Advanced Ovarian Cancer
KEY TAKEAWAYS The clinical trial IMagyn050 (NCT03038100) aimed to assess the effectiveness of Atezo versus placebo in combination with carboplatin and CPB for front-line ovarian cancer patients. Tumor biomarkers, including CD8 density and location, immune inflamed...
Defining Benefit of Rucaparib Maintenance in Newly Diagnosed Ovarian Cancer: ATHENA-MONO Phase III Study
KEY TAKEAWAYS The Phase 3 ATHENA-MONO trial (NCT03522246) demonstrated improved PFS with first-line rucaparib maintenance therapy. The primary aim was to evaluate the efficacy of rucaparib 1L maintenance treatment across all patients, irrespective of their baseline...
Exploring the Safety and Efficacy of Adjuvant Giredestrant: The lidERA Breast Cancer Trial
KEY TAKEAWAYS LidERA is a global, randomized, open-label, multicenter phase III trial for patients with medium- and high-risk stage I-III histologically confirmed ER+/HER2- eBC. The trial's primary aim is to assess the safety and efficacy of adjuvant giredestrant...
Maintenance Selinexor vs Placebo in Endometrial Cancer: SIENDO Study
KEY TAKEAWAYS The phase 3 SIENDO study evaluated the efficacy of SEL as a maintenance therapy in patients with advanced or recurrent EC. The study's method involves administering SEL as maintenance therapy to 263 patients with advanced or recurrent EC after one...
Phase III Trial Comparing 177Lu-Edotreotide with Standard Care for GEP-NETs (Grades 2 and 3)
KEY TAKEAWAYS The COMPOSE study is a phase III clinical trial to assess the effectiveness, safety, and patient-reported outcomes of 177 Lu-edotreotide PRRT. GEP-NETs account for 70% of neuroendocrine tumors and often present with metastatic disease and limited...
Cabozantinib vs Placebo in RAIR DTC Patients: Outcomes by Prior Lenvatinib Duration
KEY TAKEAWAYS The primary aim of the COSMIC-311 study, a phase 3 trial, was to compare the PFS and ORR of cabozantinib (C) and placebo (P) in patients with RAIR DTC who had progressed after prior VEGFR-targeted treatment. The outcome showed that C maintained better...
SELECT ONCOLOGY JOURNAL ARTICLES
Cardiovascular toxicities associated with bispecific T-cell engager therapy
Cardiovascular toxicities associated with bispecific T-cell engager therapy
Background Bispecific T-cell engagers (BTEs) are novel agents used to treat hematological malignancies. Early trials were underpowered to define cardiovascular adverse events (CVAE) and no large-scale studies systematically examined the CVAEs associated with BTEs. Methods Leveraging the US …
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS >=1%: results from a multicenter, open-label, phase 2 trial
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS >=1%: results from a multicenter, open-label, phase 2 trial
Background The combination of immune-checkpoint inhibitors and antiangiogenic agents can synergistically modulate the tumor microenvironment and represents a promising treatment option. Here, we evaluated the efficacy and safety of camrelizumab plus famitinib (a receptor tyrosine kinase …
Advancements in NSCLC: From Pathophysiological Insights to Targeted Treatments
Advancements in NSCLC: From Pathophysiological Insights to Targeted Treatments
With the global incidence of non-small cell lung cancer (NSCLC) on the rise, the development of innovative treatment strategies is increasingly vital. This review underscores the pivotal role of precision medicine in transforming NSCLC management, …
Early Experience With Two-Fraction Spine Stereotactic Body Radiation Therapy in Treating Spinal Metastases
Early Experience With Two-Fraction Spine Stereotactic Body Radiation Therapy in Treating Spinal Metastases
Introduction: Spinal metastases are common in metastatic cancer, affecting around 40% of patients. The primary treatment involves radiation therapy, transitioning from conventional external beam radiation therapy (EBRT) to stereotactic body radiation therapy (SBRT) for its …